Pirfenidone for radiation lung injury with or without immune pneumonia
Part of Lungs & breathing clinical trials.
This trial tests if pirfenidone capsules can help treat lung damage caused by radiation therapy, with or without immune-related pneumonia. It may be suitable for people with mild to moderate lung function impairment who have recently developed radiation lung injury.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had radiation therapy to your chest for cancer and have been diagnosed with radiation-induced lung injury (grade 2–3) with or without immune pneumonia.
- Your lung function test shows mild to moderate impairment (DLCO 40% to less than 80% of predicted).
- Your lung injury started less than 2 months ago.
- You are able to take pills by mouth and have an estimated survival of at least 6 months.
- Your blood counts and liver/kidney function are within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
Hear when a new Radiation-induced Lung Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.